Admission blood revealed a lipase of 1367 U/L (normal reference: 13-60 U/L), alanine transaminase of 64 IU/L (normal reference: 1- 35 IU/L), bilirubin of 6 umol/L (normal reference: 0-21 umol/L), alkaline phosphatase of 64 U/L (normal reference: 30-130 U/L), adjusted calcium of 2.26 mmol/L (normal reference: 2.20-2.60 mmol/L), and triglycerides of 1.5 mmol/L (normal reference: 0.0-1.6 mmol/L) (Table 1)
Among anti-obesity medications, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have attracted particular attention
While topical corticosteroids can give short-term relief due to vasoconstrictive and anti-inflammatory action, they will aggravate symptoms over the following weeks
In the landmark SELECT trial in 2023, the scope of GLP-1RAs was expanded to assess cardiovascular risk in patients with preexisting cardiovascular disease who were overweight or obese without type 2 diabetes [48]
Taking into consideration the structural and functional perturbations of the NVU in neurodegenerative disorders, some of the approaches could address the direct and indirect effects of GLP-RAs on the physiology of NVU
